跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 255 条关于
“NBIP-01435”
全部
255
临床试验
156
药物
89
机构
1
资讯
9
去年
Neurocrine Biosciences Initiates Phase 1 Trial for Long-Acting CAH Treatment NBIP-01435
去年
Neurocrine Biosciences Advances CAH Treatment Portfolio with Long-Acting Injectable Therapy
4个月前
Neurocrine Biosciences Initiates Phase 1 Trial for Novel CRF2 Agonist NBIP-2118 in Obesity Treatment
上个月
Neurocrine Biosciences Launches Phase I Trial of GLP-1/GIP/Glucagon Triple Agonist NBIP-1968 for Obesity
2年前
Neurocrine's NBI-1117568 Shows Promise in Phase II Schizophrenia Trial
去年
NAIP Breaks Ground on State-of-the-Art Pharmaceutical Research Centre in Nigeria's Anambra State
去年
BiPER Therapeutics Secures €800,000 to Advance BiP Inhibitor for Gastrointestinal Cancers
10个月前
Neurocrine's NBI-1070770 Fails to Meet Primary Endpoint in Phase II Major Depressive Disorder Trial
23天前
FDA Clears IND for Neurocrine and Nxera's Oral M1 Agonist NBI-1117567 in Alzheimer's Cognition